Fibrinogen catabolism within the procoagulant VX-2 tumor of rabbit lung in vivo: Effluxing fibrin(ogen) fragments contain antiangiogenic activity

Journal of Laboratory and Clinical Medicine

Volumn 143, Issue 4, 2004, Pages 241-254

  Hatton, Mark W C ^a   Southward, Suzanne M R ^b   Legault, Kimberly J ^b   Ross, Bonnie L ^b   Clarke, Bryan J ^b   Bajzar, Laszlo ^b   Blajchman, Morris A ^b   Singh, Gurmit ^b   Richardson, Mary ^b  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPLASMIN; BIOLOGICAL MARKER; FIBRINOGEN; IODINE 125; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BIOACCUMULATION; CHICK EMBRYO; CHORIOALLANTOIS; CONTROLLED STUDY; DENSITOMETRY; FIBRINOGEN BLOOD LEVEL; FIBRINOGEN METABOLISM; FIBRINOLYSIS; IMMUNOBLOTTING; IN VIVO STUDY; LUNG TUMOR; MOLECULAR WEIGHT; NONHUMAN; PROTEIN DEGRADATION; PROTEIN FUNCTION; RABBIT; SOLID TUMOR;

EID: 1942439974     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lab.2004.01.006     Document Type: Article

References (41)

1. Rous P, Beard JW. The progression to carcinoma of virus-induced rabbit papillomas (Shope). J Exp Med 1935;62:523-48.
2. Rous P, Kidd JG, Smith WE. Experiments on cause of rabbit carcinomas derived from virus-induced papillomas. Loss by VX2 carcinoma of power to immunize hosts against papilloma virus. J Exp Med 1952;96:159-74.
3. Hatton MWC, Ross B, Bardossy L, Southward SMR, DeReske M, Richardson M, et al. The procoagulant state of the VX-2 tumor in the rabbit lung in vivo: relative accumulation of fibrinogen, prothrombin, plasminogen, antithrombin, and heparin co-factor II within the tumor. Thromb Haemost 1999;82:1694-702.
4. Dvorak HF. Tumours: Wounds that do not heal. Similarities between tumour stroma generation and wound healing. N Eng J Med 1986;315:1650-9.
5. Nagy JA, Morgan ES, Herzberg KT, Manseau EJ, Dvorak AM, Dvorak HF. Pathogenesis of ascites tumor growth: angiogenesis, vascular remodelling, and stroma formation in the peritoneal lining. Cancer Res 1995;55:376-85.
6. Thompson WD, Smith EB, Stirk CM, Marshall FI, Stout AJ, Kocchar A. Angiogenic activity of fibrin degradation products is located in fibrin fragment E. J Pathol 1992;168:47-53.
7. Bootle-Wilbraham CA, Tazzyman S, Marshall JM, Lewis CE. Fibrinogen E fragment inhibits the migration and tubule formation of human dermal microvascular endothelial cells in vitro. Cancer Res 2000;60:4719-24.
8. Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000;96: 3302-9.
9. Jain RK. Vascular and interstitial physiology of tumours: role in cancer detection and treatment. In: Bicknell R, Lewis CE, Ferrara N, ed. Tumour angiogenesis. Oxford, UK: Oxford University Press; 1997:45-59.
10. Hatton MWC, Southward SMR, Ross BL, Legault K, Marien L, Korbie D, et al. Angiostatin II is the predominant glycoform in the pleural effusates of rabbit VX-2 lung tumors. J Lab Clin Med 2002;139:316-23.
11. Witmer MR, Hadcock SJ, Peltier SL, Winocour PD, Richardson M, Hatton MWC. Altered levels of antithrombin III and fibrinogen in the aortic wall of the alloxan-induced diabetic rabbit: evidence of a prothrombotic state. J Lab Clin Med 1992;119: 221-30.
12. Sodetz JM, Brockway WJ, Castellino FJ. Multiplicity of rabbit plasminogen: physical characterization. Biochemistry 1972;11: 499-508.
13. Hatton MWC, Regoeczi E. Some observations on the affinity chromatography of rabbit plasminogen. Biochim Biophys Acta 1974;359:55-65.
14. Hatton MWC, Day S, Southward SMR, DeReske M, Ross B, Seidlitz E, et al. Metabolism of rabbit angiostatin glycoforms I and II in rabbits: angiostatin I leaves the intravascular space faster and appears to have greater antiangiogenic activity than angiostatin II. J Lab Clin Med 2001;138:83-93.
15. Hatton MWC, Moar SL, Richardson M. De-endothelialization in vivo initiates a thrombogenic reaction at the rabbit aorta surface. Correlation of uptake of fibrinogen and antithrombin III with thrombin generation by the exposed subendothelium. Am J Pathol 1989;135:499-508.
16. Hatton MWC, Regoeczi E. The inactivation of thrombin and plasmin by antithrombin III in the presence of Sepharose-heparin. Thromb Res 1977;10:645-60.
17. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1995;270:14477-84.
18. Longstaff C. Studies on the mechanism of action of aprotinin and tranexamic acid as plasmin inhibitors and antifibrinolytic agents. Blood Coag Fibrinol 1994;5:537-42.
19. Olfert ED, Cross BM, McWilliam AA, eds. Guide to the care and use of experimental animals. Vol 1, ed 2. Canadian Council on Animal Care, Ottawa; 1993.
20. Fraker PJ, Speck JC. Protein and cell membrane iodinations with a sparingly soluble chloramide, 1, 3, 4, 6-tetrachloro-3a, 6a-diphenylglycoluril. Biochem Biophys Res Commun 1978;80: 849-57.
21. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
22. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets. Procedure and some applications. Proc Natl Acad Sci U S A 1979; 76:4350-4.
23. Blake MS, Johnston KH, Russell-Jones GJ, Gotschlich EC. A rapid sensitive method for detection of alkaline phosphatase conjugated antibody on western blots. Anal Biochem 1984;136: 175-9.
24. Furlan M, Beck EA. Plasmic degradation of human fibrinogen I. Structural characterization of degradation products. Biochim Biophys Acta 1972;263:631-44.
25. Budzynski AZ, Marder VJ, Shainoff JR. Structure of plasmic degradation products of human fibrinogen. J Biol Chem 1974; 249:2294-302.
26. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
27. Richardson M, Gunawan J, Hatton MWC, Seidlitz E, Hirte HW, Singh G. Malignant ascites fluid (MAF), including ovarian cancer-associated MAF, contains angiostatin and other factors that inhibit angiogenesis. Gynecol Oncol 2002;86:279-87.
28. Hatton MWC, Southward S, Ross-Ouellet B, Richardson M, Winocour PD. Catabolism of unglycated and naturally glycated forms of rabbit fibrinogen: their interaction with the healthy and deendothelialized aorta wall in normal and diabetic rabbits. J Lab Clin Med 1993;121:588-97.
29. Bootle-Wilbraham CA, Tazzyman S, Thompson WD, Stirk CM, Lewis CE. Fibrin fragment E stimulates the proliferation, migration and differentiation of human microvascular endothelial cells in vitro. Angiogenesis 2001;4:269-75.
30. Hatton MWC, Day S, Ross B, Southward SMR, DeReske M, Richardson M. Plasminogen II accumulates five times faster than plasminogen I at the site of a balloon deendothelializing injury in vivo to the rabbit aorta: comparison with other hemostatic proteins. J Lab Clin Med 1999;134:260-6.
31. Karges HE, Funk KA, Ronneberger H. Activity of coagulation and fibrinolysis in animals. Arzneimittelforschung 1994;44:793-7.
32. Kerckaert J-P, Bayard B. Glycan uniformity within molecular variants of transferrin with distinct affinity for concanavalin-A. Biochem Biophys Res Commun 1982;105:1023-30.
33. 2tu-PA expressed in Chinese hamster ovary cells. FEBS Lett 1993;212:639-56.
34. Pohl G, Kenne L, Nilsson B, Einarsson M. Isolation and characterization of three different carbohydrate chains from melanoma tissue plasminogen activator. Eur J Biochem 1987;170: 69-75.
35. Senger DR, Van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 1993;12:303-24.
36. Westphal JR, Van't Hullenar R, Guerts-Mospot A, Sweep FCGJ, Verheigen JH, Bussemakers MMG, et al. Angiostatin generation by human tumor cell lines: involvement of plasminogen activators. Int J Cancer 2000;86:760-7.
37. Browder T, Folkman J, Pirie-Shepherd S. The hemostatic system as a regulator of angiogenesis. J Biol Chem 2000;275:1521-4.
38. Cao Y. Endogenous angiogenesis inhibitors and their therapeutic implications. Int J Biochem Cell Biol 2001;33:357-69.
39. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med 1996;2:689-92.
40. Ardaillou N, Dray L, Budzynski AZ, Marder VJ, Larrieu MJ. The half-life of plasmic degradation products of human fibrinogen in rabbits. Thromb Haemost 1977;37:201-9.
41. Brommer EJP, Engbers J, van der Laarse A, Nieuwenhuizen W. Survival of fibrinogen degradation products in the circulation after thrombolytic therapy for acute myocardial infarction. Fibrinolysis 1987;1:149-53.